Roche has entered into a strategic development and commercialization agreement with Alnylam Pharmaceuticals to advance the latter’s investigational RNA interference therapeutic zilebesiran for hypertension, the companies announced Monday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,